Journal
BIOMARKERS
Volume 16, Issue 4, Pages 289-301Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/1354750X.2011.561366
Keywords
Connective tissue growth factor; fibrosis; biomarker; sandwich ELISA
Categories
Funding
- FibroGen Inc.
- San Francisco, CA, USA
Ask authors/readers for more resources
Background: Connective tissue growth factor (CTGF) has been identified as a key factor in the pathogenesis of diseases with significant fibrosis-related complications such as hepatitis, diabetes and renal transplantation. Increasing evidence shows that CTGF levels in plasma, serum and urine have promising biomarker applicability in these disorders. Objective: To present an overview of current knowledge on CTGF in various patient populations and the technical aspects of CTGF measurement by enzyme-linked immunosorbent assay (ELISA). Method: We performed a comprehensive literature search by using electronic bibliographic databases. Conclusion: CTGF is associated with disease severity parameters and outcome in fibrotic disease and may have diagnostic and prognostic values. However, CTGF ELISA needs standardization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available